

Elina Parri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6771430/publications.pdf>

Version: 2024-02-01

11
papers

286
citations

1651377

6
h-index

1905433

7
g-index

11
all docs

11
docs citations

11
times ranked

514
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells. <i>Blood Advances</i> , 2021, 5, 1862-1875.	2.5	5
2	Identification of novel regulators of STAT3 activity. <i>PLoS ONE</i> , 2020, 15, e0230819.	1.1	12
3	Identification of novel regulators of STAT3 activity. , 2020, 15, e0230819.		0
4	Identification of novel regulators of STAT3 activity. , 2020, 15, e0230819.		0
5	Identification of novel regulators of STAT3 activity. , 2020, 15, e0230819.		0
6	Identification of novel regulators of STAT3 activity. , 2020, 15, e0230819.		0
7	Chemogenomic Analysis of the Druggable Kinome and Its Application to Repositioning and Lead Identification Studies. <i>Cell Chemical Biology</i> , 2019, 26, 1608-1622.e6.	2.5	14
8	Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from <i>Kras</i> -driven lung tumours. <i>Journal of Pathology</i> , 2018, 245, 101-113.	2.1	19
9	Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions. <i>Cell Chemical Biology</i> , 2018, 25, 224-229.e2.	2.5	124
10	Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors. <i>PLoS Computational Biology</i> , 2017, 13, e1005678.	1.5	84
11	Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. <i>Oncotarget</i> , 2017, 8, 97516-97527.	0.8	28